FDA Approves Bemotrizinol (BEMT): What Sunscreen Brands Must Do to Sell in the U.S.

Alok Naik, MS- Regulatory Affairs
1 day ago
4 min read

The first time in more than two decades, the FDA has added a new active ingredient to the U.S. over-the-counter (OTC) sunscreen monograph.

On June 9, 2026, the agency issued Final Administrative Order OTC000039, adding bemotrizinol — a broad-spectrum UV filter long used in Europe and Asia — to OTC Monograph M020 for sunscreen drug products. The order takes effect August 9, 2026.

It's a genuine milestone.

It's also where most brands are about to make expensive mistakes. The ingredient is the easy part. Selling a bemotrizinol sunscreen legally in the United States means clearing a stack of OTC drug obligations that have nothing to do with the molecule itself — and a market-timing detail almost no one is talking about.

What the FDA actually did

Added bemotrizinol to OTC Sunscreen Monograph M020 as a permitted active ingredient, at concentrations up to 6%.

Determined it GRASE (generally recognized as safe and effective) for adults and children 6 months and older — broad-spectrum UVA/UVB, highly photostable, low skin absorption.

Cleared it through the CARES Act administrative-order pathway — the streamlined process that replaced the decades-long rulemaking that previously stalled new filters. Bemotrizinol is the first new sunscreen active to go through it.

The requestor, DSM, will market the ingredient as PARSOL Shield, with U.S. launches expected later in 2026.

The headline writes itself: first new U.S. sunscreen filter in 25+ years. The business reality is more nuanced.

The detail most brands are missing: the 18-month exclusivity

Approval does not mean every brand can drop bemotrizinol into a U.S. product tomorrow.

Under the OTC monograph order rules, the requestor receives roughly 18 months of exclusivity tied to its data submission.

During that window, other manufacturers can't rely on that data package to market their own bemotrizinol sunscreens. In practice, that pushes broad third-party U.S. entry to around late 2027 — unless a company licenses the ingredient or independently submits its own qualifying data.

So the real calendar looks like this:

Now → August 2026: order finalized; effective date August 9, 2026.

2026 → late 2027: exclusivity window. Early movers prepare, build their regulatory file, and line up supply.

~Late 2027 onward: broad market access opens for other brands relying on the monograph.

That timeline is the opportunity. The brands that win the post-exclusivity rush will be the ones whose FDA registrations, listings, labeling, and U.S. Agent are already in place.

The part brands underestimate: in the U.S., sunscreen is a drug

In most of the world, sunscreens are cosmetics. In the United States, sunscreens are OTC drugs — and adding bemotrizinol to the monograph does not waive any of the obligations that come with that.

Before a bemotrizinol sunscreen can be legally distributed, the responsible parties generally need:

Establishment registration — every facility that manufactures or processes the drug must register with the FDA.

Drug listing (NDC + SPL) — each product listed electronically in Structured Product Labeling, with a National Drug Code.

A compliant Drug Facts panel — active ingredients, purpose, uses, warnings, directions in the exact OTC format. This is where most foreign labels fail.

SPF and broad-spectrum testing on the final formulation, per the monograph methods.

Current Good Manufacturing Practice (cGMP) for OTC drugs.

A U.S. Agent — any foreign establishment must designate a U.S.-based agent as its FDA point of contact.

Serious adverse event reporting — generally within 15 business days.

None of this is optional, and none of it disappears because the active is monograph-approved. A product that skips it isn't an approved sunscreen — it's a misbranded or unapproved drug.

Who this affects right now

International brands already using bemotrizinol abroad.

Korean, Japanese, and EU lines that already contain the filter will want U.S. versions. Your global formula may be close — but your label, testing, and FDA filings won't be.

Contract and private-label manufacturers.

You're about to field "can you make me a U.S. bemotrizinol sunscreen?" requests from brand owners who don't understand the OTC drug pathway. Whoever can answer the compliance question wins the work.

Amazon and DTC sunscreen startups.

Listing a sunscreen for U.S. sale triggers every obligation above, regardless of where it's made.

Foreign OEMs shipping directly into the U.S. The highest-stakes group: establishment registration, drug listing, a U.S. Agent, and an OTC compliance review before product crosses the border.

What to do now — even before exclusivity lifts

Confirm your pathway and timeline — monograph (exclusivity clock), license, or your own data. It drives everything else.
Audit your existing label against the U.S. Drug Facts format. Assume it needs changes.
Map your FDA obligations — registration, listing/SPL, U.S. Agent, AE reporting — and who owns each.
Line up final-formulation SPF and broad-spectrum testing.
Build the file now so you're submission-ready the moment your window opens.

Get the checklist

We've turned this into a practical Bemotrizinol (BEMT) U.S. Market-Entry Compliance Checklist — every step to sell a sunscreen in the United States, with the BEMT-specific timeline built in.

Download the free checklist → and we'll point you to the right next step for your situation.

If you'd rather hand it off, Axentra's U.S. Market Entry Package covers it end to end: formula regulatory assessment, Drug Facts and label review, establishment registration, drug listing and SPL submission, U.S. Agent service, and ongoing compliance support — so your product is ready the day your market opens.

Frequently asked questions

When can I actually sell a bemotrizinol sunscreen in the U.S.?

The order takes effect August 9, 2026. But because of the ~18-month exclusivity tied to the original data submission, most other brands relying on the monograph realistically reach the market around late 2027 — unless they license the ingredient or submit their own data. Use the window to prepare your filings.

Is my European or Korean sunscreen automatically allowed now?

No. The active being permitted is only one piece. Your product still needs a compliant Drug Facts panel, U.S. SPF/broad-spectrum testing, establishment registration, drug listing, and (for foreign firms) a U.S. Agent. Most international labels need changes first.

Do foreign sunscreen manufacturers need a U.S. Agent?

Yes. Any foreign establishment that registers with the FDA must designate a U.S. Agent as its point of contact with the agency.

What's required to sell any sunscreen in the U.S., bemotrizinol or not?

Establishment registration, drug listing (NDC/SPL), a compliant Drug Facts label, SPF and broad-spectrum testing, OTC cGMP, a U.S. Agent for foreign firms, and serious adverse event reporting.

Does the bemotrizinol approval change any of those obligations?

No. It adds a permitted active ingredient; it does not waive monograph or general OTC drug requirements.